Transcriptomics

Dataset Information

0

Kmt2d deficiency promotes acute myeloid leukemia development and maintenance


ABSTRACT: The histone-3 lysine-4 methyltransferase KMT2D is frequently mutated in human cancers. However, knowledge of its role in the initiation and maintenance of acute myeloid leukemia (AML) is incomplete. Here, we show that KMT2D is generally downregulated in human AML. Using shRNA and CRISPR/Cas9 technologies, we show that Kmt2d loss, by cooperating with Trp53 and Nf1 loss, promoted mouse acute myeloid leukemogenesis through a differentiation block of hematopoietic stem and progenitor cells. Furthermore, using a doxycycline-induced shRNA system, we show that restoring Kmt2d impairs AML maintenance. Multi-omics analyses of Kmt2d-deficient and -restored AML cells showed that Kmt2d, via histone methyltransferase activity and chromatin remodeling, epigenetically regulates the expression of genes controlling hematopoietic stem cell differentiation. Lastly, we showed that 3-Deazaneplanocin A, a histone methyltransferase EZH2 inhibitor, could specifically repress Kmt2d-deficient AML cell growth and reverse pro-leukemia programs. Thus, our study indicate Kmt2d is a tumor suppressor, whose downregulation promotes AML development through differentiation blockage.

ORGANISM(S): Mus musculus

PROVIDER: GSE147210 | GEO | 2022/09/18

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2014-07-22 | E-GEOD-57147 | biostudies-arrayexpress
2014-07-22 | GSE57147 | GEO
2020-02-25 | PXD017054 | Pride
2022-09-30 | GSE192629 | GEO
2015-08-04 | E-GEOD-71688 | biostudies-arrayexpress
2019-11-27 | PXD014387 | Pride
2015-08-04 | E-GEOD-71687 | biostudies-arrayexpress
2014-09-17 | E-GEOD-61468 | biostudies-arrayexpress
2024-06-03 | PXD050623 | Pride
2023-03-08 | PXD039474 | Pride